NCT06148298 Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
| NCT ID | NCT06148298 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Central Florida |
| Condition | Cancer of Pancreas |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-05-24 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2023-05-24 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.
Eligibility Criteria
Inclusion Criteria: * 18 years old or older * Pancreatic cancer patients Exclusion Criteria: * Children may not register * Persons who are unable to consent may not register
Contact & Investigator
Kersten Schroeder, PhD
PRINCIPAL INVESTIGATOR
University of Central Florida
Frequently Asked Questions
Who can join the NCT06148298 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer of Pancreas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06148298 currently recruiting?
Yes, NCT06148298 is actively recruiting participants. Contact the research team at amoy.fraser@ucf.edu for enrollment information.
Where is the NCT06148298 trial being conducted?
This trial is being conducted at Orlando, United States.
Who is sponsoring the NCT06148298 clinical trial?
NCT06148298 is sponsored by University of Central Florida. The principal investigator is Kersten Schroeder, PhD at University of Central Florida. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.